CClinicalTrials.gg
RecruitingNCT04494672Updated Sep 9, 2026

A Study to Verify if the Surgery for the Proximal Femur Fracture Can be Improved With the Help of a Navigation System

An interventional study of Intramedullary nailing with ADAPT system and Intramedullary nailing without ADAPT system in Femoral Fracture, sponsored by Christian Candrian. Recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Christian Candrian · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The ADAPT system is a software that calculate a virtual 3D reconstruction of the femoral head without additional radiation. It automatically detects the used implant and its position relative to the femoral head, helping the surgeon to achieve an optimal proximal screw positioning in the femoral head. The investigators want to verify if with the addition of the ADAPT system the investigators can improve screw placement and reduce surgery time and radiation exposure.

Read the detailed description

This study is a 2-arm randomized controlled trial comparing intramedullary nailing of proximal fracture of the femur (AO classified as 31 A1.3 , 31 A2.1, 31 A2.2 31 A2.3, 31 A3.1, 31 A3.2, 31 A3.3) performed with the ADAPT system (arm-A) and those performed without (arm-B).

The ADAPT system has been developed with the aim to reduce the rate of complications in intramedullary nailing and its usefulness has been previously explored only in two underpowered randomized controlled trials. Thanks to the possibility to track screw placement in real-time, allowing improved screw placement, the ADAPT system could be a valid tool, in order to minimize radiation exposure, surgical time, and rate of complications.

All the patients undergoing intramedullary nailing at the Ospedale Regionale di Lugano satisfying the eligibility criteria reported at section 7.1 will be enrolled in the study and randomly allocated (allocation ratio 1:1) to receive preoperatively:

  • Intramedullary nailing with ADAPT system (arm-A)
  • Intramedullary nailing without ADAPT system (arm-B) Patients and physicians evaluating the results will be blinded to the assigned group.

The total number of patients enrolled will be 96 (48 arm-A, 48 arm-B). After surgery, data about duration of the procedure, intraoperative blood loss, satisfaction of the surgeon and radiation exposure time will be collected.

Fracture healing, and rate of complications (cut-through and cut out) will be evaluated during all the follow-up visits, alongside VAS and a functional evaluation of the injured hip through the Oxford Hip score.

All treatment related adverse events will be reported up to follow-up visit 4, i.e. up to 12 ± 1 months.

Every patient will be involved in the trial for 1 year. The expected time to complete the trial is 4 years: 3 years for patient enrolment and 1 year to complete the last follow-up

02

Conditions studied

  • Femoral Fracture

Browse trials for

03

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients undergoing unilateral primary intramedullary nailing at the Ospedale Regionale di Lugano.
  • Patients aged 50-85 years old.
  • Patients with a BMI >18 and \<35.
  • Patients able to provide informed consent and follow all the study procedures as indicated by the protocol.
  • Radiological evidence of proximal fracture of the femur, AO classified as 31 A1.3, 31 A2.1, 31 A2.2, 31 A2.3, 31 A3.1, 31 A3.2, 31 A3.3.

Exclusion criteria

Exclusion Criteria:

  • Other clinically significant concomitant disease states (e.g. renal failure, major hepatic dysfunction, life-threatening cardiovascular disease, etc..).
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Previous enrolment into the current study.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Intramedullary nailing with ADAPT system (arm-A)

    A commercial product, namely ADAPT will be used as investigation product in arm-A

    Procedure: Intramedullary nailing with ADAPT system

  • Active comparator
    Intramedullary nailing without ADAPT system (arm-B)

    No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B

    Procedure: Intramedullary nailing without ADAPT system

Interventions

  • ProcedureIntramedullary nailing with ADAPT system

    Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively

  • ProcedureIntramedullary nailing without ADAPT system

    Intramedullary nailing without ADAPT system

05

What researchers measure

Primary outcomes

  1. TAD (tip to apex) index at the post-operative X-Ray control prior discharge

    The primary outcome of the study is the TAD (tip to apex) index at the post-operative X-Ray control prior discharge. The TAD is the tip-apex distance, which is the sum of the distance from the tip of the lag screw to the apex of the femoral head on an anteroposterior radiograph and this distance on a lateral radiograph, after controlling for magnification. The percentage of cut-outs has been correlated directly to both the severity of proximal femoral fractures and the TAD.

    Time frame: immediately after the surgery

Secondary outcomes

  1. time of the procedure

    time

    Time frame: immediately after the surgery

  2. intraoperative blood loss

    intraoperative blood loss

    Time frame: during the surgery

  3. intraoperative radiation time

    intraoperative radiation time

    Time frame: during the surgery

  4. surgeon satisfaction on the satisfaction Numerical Rating Scale (NRS scale)

    The satisfaction NRS is a self-assessment scale in which surgeons rate their satisfaction on an 11-point numerical scale from 0 (completely dissatisfied) to 10 (completely satisfied). The satisfaction NRS will be administered after surgery

    Time frame: immediately after the surgery

  5. non-union

    fracture not alligned

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

  6. cut-through rate

    cut-through rate

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

  7. cut-out rate

    cut-out rate

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

  8. VAS

    Visual pain analogue scale, \[from 0 (no pain) to 10 (worst pain)\]

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

  9. Oxford Hip Score, [from 0 (severe hip arthritis) to 48 ( satisfactory joint function)]

    Hip function

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

Other outcomes

  1. re-fracture rates

    re-fracture rates

    Time frame: at 6 weeks, 3 months, 6 months and 1-year

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No — not foreseen

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04494672
Lead sponsor
Christian Candrian
Responsible party
Christian Candrian (Prof. Dr. Med., Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Jul 31, 2020
Start date
Sep 28, 2020
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Christian Candrian, MD
Contact
RicercaOrtopedia.ORL@eoc.ch
0041918117029
Christian Candrian, MD
principal investigator · Ente Ospedaliero Cantonale, Bellinzona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion